Skip to main content
HR 6260 116th Congress House Health Cardiovascular and respiratory health Congressional oversight Drug safety, medical device, and laboratory regulation Emergency medical services and trauma care Infectious and parasitic diseases

Reciprocity Ensures Streamlined Use of Lifesaving Treatments for Coronavirus Patients Act of 2020

Introduced: April 17, 2020 Introduced by: Roy, Chip Republican · Texas See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 12, 2020
Introduced in House
Mar 12, 2020
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Rules, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Reciprocity Ensures Streamlined Use of Lifesaving Treatments for Coronavirus Patients Act of 2020

This bill establishes a reciprocal marketing approval process that allows for the sale of a drug, biological product, or medical device that has not been approved by the Food and Drug Administration (FDA) if the product is approved for sale in another country for the treatment or prevention of COVID-19 (i.e., coronavirus disease 2019) and there is an unmet need relative to certain diseases.

Specifically, the bill requires the product's sponsor to demonstrate, among other things, that

  • the product has been approved for the treatment or prevention of COVID-19 or another disease of epidemic potential,
  • the approval is in one of the specified countries,
  • the FDA and listed countries have not withdrawn approval because of safety or effectiveness concerns, and
  • there is a public health or unmet medical need for the product.

The FDA may only decline approval if the FDA determines that the product is not safe or effective. The FDA must make such a determination not later than 30 days after receiving a request.

Congress may pass a joint resolution to grant reciprocal marketing approval of a product that the FDA declines to approve through the reciprocal process.

What's happening now March 12, 2020

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Rules, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

 Related & companion bills 4
  • HR 6258 Related bill Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2020
  • S 4537 Related bill RECOVERY Act
  • S 2161 Related bill Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019
  • S 3545 Identical bill Reciprocity Ensures Streamlined Use of Lifesaving Treatments for Co­ro­na­vi­rus Patients Act of 2020
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 1
All 1 Republican 1
R
Schweikert, David
Arizona · Apr 17, 2020
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 6260: Reciprocity Ensures Streamlined Use of Lifesaving Treatments for Coronavirus Patients Act of 2020. 116th Congress. Open America. https://openamerica.io/bill/116-HR-6260/
MLA
"H.R. 6260: Reciprocity Ensures Streamlined Use of Lifesaving Treatments for Coronavirus Patients Act of 2020." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-6260/.
Bluebook (legal)
H.R. 6260, 116th Cong. (2026), https://openamerica.io/bill/116-HR-6260/.
Markdown link
[H.R. 6260: Reciprocity Ensures Streamlined Use of Lifesaving Treatments for Coronavirus Patients Act of 2020](https://openamerica.io/bill/116-HR-6260/)
Report a problem